Market Cap | 73.58M | P/E | - | EPS this Y | 30.40% | Ern Qtrly Grth | - |
Income | -22.21M | Forward P/E | -4.05 | EPS next Y | 52.30% | 50D Avg Chg | 3.00% |
Sales | 709k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 3.00% |
Dividend | N/A | Price/Book | 4.48 | EPS next 5Y | - | 52W High Chg | -51.00% |
Recommedations | 2.00 | Quick Ratio | 1.41 | Shares Outstanding | 3.31M | 52W Low Chg | 39.00% |
Insider Own | 18.30% | ROA | -66.49% | Shares Float | 1.53M | Beta | 0.20 |
Inst Own | 7.59% | ROE | -157.19% | Shares Shorted/Prior | 28.06K/19.29K | Price | 3.48 |
Gross Margin | 31.17% | Profit Margin | - | Avg. Volume | 168,116 | Target Price | 30.05 |
Oper. Margin | -8,598.41% | Earnings Date | - | Volume | 18,934 | Change | 3.88% |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
HC Wainwright & Co. | Buy | Dec 4, 23 |
EF Hutton | Buy | May 16, 23 |
EF Hutton | Buy | May 9, 23 |
EF Hutton | Buy | Mar 27, 23 |
EF Hutton | Buy | Jan 10, 23 |
Maxim Group | Buy | Mar 24, 22 |
EF Hutton | Buy | Jan 5, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Ross Cathy | Director Director | Jan 10 | Buy | 1.3089 | 5,000 | 6,544 | 10,000 | 01/11/24 |
Baluch Khoso | Director Director | Dec 28 | Buy | 1.41 | 10,000 | 14,100 | 15,000 | 01/02/24 |
Hare Joshua | Chief Scientific Off.. Chief Scientific Officer | Sep 21 | Option | 3.00 | 5,000 | 15,000 | 7,828,263 | 09/22/23 |
Lehr Paul T | General Counsel, Sec.. General Counsel, Secretary | Sep 20 | Option | 3.00 | 2,000 | 6,000 | 144,213 | 09/21/23 |
Hare Joshua | Chief Scientific Off.. Chief Scientific Officer | Sep 12 | Option | 3.00 | 30,000 | 90,000 | 7,823,263 | 09/14/23 |
Soffer Rock | Director Director | Sep 08 | Option | 3.00 | 30,000 | 90,000 | 702,351 | 09/12/23 |
Clavijo James | CFO and Treasurer CFO and Treasurer | Jun 27 | Sell | 3.47 | 23,532 | 81,656 | 47,303 | 06/29/23 |
Clavijo James | CFO and Treasurer CFO and Treasurer | Jun 03 | Sell | 8.26 | 36,955 | 305,248 | 79,619 | 06/07/22 |
Soffer Rock | Director Director | May 20 | Sell | 7.78 | 19,500 | 151,710 | 672,351 | 05/24/22 |
Hare Joshua | Chief Scientific Off.. Chief Scientific Officer | Apr 18 | Sell | 10 | 20,000 | 200,000 | 7,913,263 | 04/20/22 |
Soffer Rock | Director Director | Oct 11 | Buy | 3.59 | 19,900 | 71,441 | 51,757 | 10/13/21 |